Mammography remains the foundation of breast cancer screening, and for many patients the technology is diagnostically sufficient. But for a significant population, mammographic sensitivity falls short, and the impact of that can mean the difference between detecting or missing breast cancer in its early, most treatable stages.
Approximately 47% of the U.S. screening population has dense breast tissue, including BI-RADS categories C and D.1 Mammographic sensitivity decreases as density rises. Across all patients, the sensitivity of mammography is reported at roughly 80%, but drops to as low as 30% in extremely dense breasts.1 Tomosynthesis improves on traditional 2D mammography but still reports sensitivity of just 48% in extremely dense tissue.2 That means that cancer could be missed in as many as 50% of women with dense breasts undergoing mammography alone.2
All of the above supports the rationale established in 2024 by the FDA’s Mammography Quality Standards Act, which outlines the need for supplemental screening for dense breast patients and requires the distribution of patient density notifications.3 Those notifications direct a substantial share of patients back to their OB/GYN for information about additional imaging. Two common solutions to that additional screening – breast MRI and handheld ultrasound – each come with their own challenges for both patients and providers.
The Limitations of Breast MRI & Handheld Ultrasound in Breast Cancer Detection
- Breast MRI offers a high level of sensitivity for breast cancer screening, but its constraints are practical rather than diagnostic. MRI requires intravenous gadolinium contrast, carries a higher false-positive rate, is substantially more expensive and in most cases requires prior authorization. Access is limited by scanner availability, and contraindications apply for a portion of patients.
- Handheld ultrasound adds approximately 5.3 cancers detected per 1,000 women screened.2 From the patient's perspective, it’s a 20- to 30-minute exam requiring a sonographer, with results that vary by operator technique. HHUS is generally available only at facilities equipped to schedule that time, limiting access and extending screening timelines for higher-risk patients.
Evaluating a More Effective Screening Alternative: ABUS
Automated breast ultrasound was recognized by the FDA in 2012 for supplemental screening in women with dense breast tissue, with reported detection rates of nearly double that of traditional mammography among dense breast patients.4 ABUS produces a standardized volumetric dataset rather than an operator-dependent manual sweep, which is what allows it to be performed outside a dedicated imaging center, including in-office for OB/GYN practices.
The in-office setting is an important one for patients, especially when faced with the anxiety and fear that often go hand-in-hand with an uncertain mammogram result and follow-up testing. The convenience and comfort that come from undergoing that additional testing in the familiar environment of their own provider’s office can contribute significantly to a positive patient experience, as well as screening follow-through.5
Detection Difference-Maker: SOFIA®
SOFIA® Automated 3D Ultrasound, from iVu Imaging, was specifically developed with that patient experience in mind, offering a uniquely comfortable and effective alternative for breast cancer screening – in the comfort of the provider’s office. Unlike other ABUS systems that require a dedicated room and typically require a specially trained operator to acquire 3-5 series of each breast, SOFIA’s unique design allows patients to lie prone on a memory-foam table during a single scan per breast.
Every scan captures the full breast in just 30 seconds, delivering high-quality, 3D images without the need for ionizing radiation or an IV. An intuitive touch-screen interface automates the scanning process for in-office imaging teams, and results are quickly readable by a local radiologist or breast teleradiologist.
SOFIA’s biggest difference-maker, however, is outcomes. A prospective study of 1,165 asymptomatic women with dense breasts using the system found the cancer detection rate doubled when SOFIA was added to mammography.6 Sensitivity rose from 58.8% with full-field digital mammography alone to 93.5% with prone ABUS added.6
SOFIA for Your OB/GYN Practice
SOFIA combines speed, accuracy and patient comfort in one seamless, 3D breast ultrasound system for earlier detection of breast cancer for all patients, including those with mammographically dense breasts. Discover why OB/GYN practices are adding SOFIA 3D Automated Breast Ultrasound to enhance in-office dense breast screening, benefiting their patient and practice. Schedule your SOFIA Demo.
Sources
- PMC11841960:"Mammographically Occult Breast Cancer in a Patient With Dense Breast Tissue” – Cureus; January 2025
- Farrokh A., et al. SOFIA: A Novel Automated Breast Ultrasound System Used on Patients in the Prone Position: A Pilot Study on Lesion Detection in Comparison to Handheld Grayscale Ultrasound. Geburtshilfe und Frauenheilkunde, 01 May 2018, 78(5):499-505 https://doi.org/10.1055/a-0600-2279
- U.S. Food and Drug Administration. Important Information: Final Rule to Amend the Mammography Quality Standards Act (MQSA). https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/important-information-final-rule-amend-mammography-quality-standards-act-mqsa
- D’Angelo, A., Gatta, G. et al. “Supine versus Prone 3D ABUS Accuracy in Breast Tumor Size Evaluation”.Tomography. 2022 Aug 12;8(4):1997-2009. doi: 10.3390/tomography8040167.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2518015/
- Gatta, G., Cappabianca, S., et al. Second-Generation 3D Automated Breast Ultrasonography (Prone ABUS) for Dense Breast Cancer Screening Integrated to Mammography: Effectiveness, Performance and Detection Rates. J Pers Med. 2021 Aug 31;11(9):875. doi: 10.3390/jpm11090875.







.webp)
.webp)

.webp)
.webp)




.webp)











